President Trump offered a more glowing assessment of the FDA in his first official State of the Union address, but also touched on two areas that could make industry feel uneasy: drug pricing and "right-to-try" legislation.
After previously slamming FDA as having burdensome regulations at a joint session of Congress last year, Trump praised the agency...








